BRPI0408063A - métodos e composições envolvendo mda-7 - Google Patents

métodos e composições envolvendo mda-7

Info

Publication number
BRPI0408063A
BRPI0408063A BRPI0408063-7A BRPI0408063A BRPI0408063A BR PI0408063 A BRPI0408063 A BR PI0408063A BR PI0408063 A BRPI0408063 A BR PI0408063A BR PI0408063 A BRPI0408063 A BR PI0408063A
Authority
BR
Brazil
Prior art keywords
methods
mda
compositions
present
compositions involving
Prior art date
Application number
BRPI0408063-7A
Other languages
English (en)
Inventor
Sunil Chada
John B Mumm
Rajagopal Ramesh
Abner Mhashilkar
Raymond E Meyn
Elizabeth Grimm
Original Assignee
Univ Texas
Introgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Introgen Therapeutics Inc filed Critical Univ Texas
Publication of BRPI0408063A publication Critical patent/BRPI0408063A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODOS E COMPOSIçõES ENVOLVENDO MDA7". A presente invenção refere-se a composições e métodos envolvendo MDA-7. Mais especificamente, a presente invenção é dirigida a composições diagnósticas, prognósticas e de tratamento terapêutico e métodos para tratamento de câncer e outros distúrbios relacionados com angiogenese (terapia anti-angiogenese). A presente invenção é também dirigida a métodos de purificação de MDA-7.
BRPI0408063-7A 2003-03-03 2004-03-02 métodos e composições envolvendo mda-7 BRPI0408063A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45225703P 2003-03-03 2003-03-03
US47452903P 2003-05-30 2003-05-30
US47615903P 2003-06-04 2003-06-04
US48686203P 2003-07-11 2003-07-11
US51528503P 2003-10-29 2003-10-29
US52850603P 2003-12-10 2003-12-10
PCT/US2004/006147 WO2004078124A2 (en) 2003-03-03 2004-03-02 Methods and compositions involving mda-7

Publications (1)

Publication Number Publication Date
BRPI0408063A true BRPI0408063A (pt) 2006-02-14

Family

ID=32966871

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408063-7A BRPI0408063A (pt) 2003-03-03 2004-03-02 métodos e composições envolvendo mda-7

Country Status (9)

Country Link
US (1) US20060134801A1 (pt)
EP (1) EP1603943A2 (pt)
JP (1) JP2006523227A (pt)
KR (1) KR20060002793A (pt)
CN (2) CN102836420B (pt)
AU (1) AU2004218407A1 (pt)
BR (1) BRPI0408063A (pt)
CA (1) CA2518150C (pt)
WO (1) WO2004078124A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
AU2003201573B2 (en) * 2002-01-22 2009-02-26 Biomatera Inc. Method of drying biodegradable polymers
EP1490101A4 (en) * 2002-03-05 2006-09-20 Univ Texas PROCESS FOR IMPROVING IMMUNE INDUCTION WITH MDA-7
WO2005047458A2 (en) 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2597329C (en) * 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2467162A4 (en) * 2009-08-21 2013-10-02 Gilead Biologics Inc THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS
CN102713601A (zh) * 2009-08-21 2012-10-03 吉联亚生物科技有限公司 体外筛选试验
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
KR20120054077A (ko) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
EP2708236A1 (en) 2012-09-12 2014-03-19 Medizinische Universität Wien Tumor treatment
WO2014197535A1 (en) * 2013-06-04 2014-12-11 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
JP6491671B2 (ja) * 2014-03-17 2019-03-27 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 核因子−κＢの移行に基づいて化合物の毒性を予測するための方法
WO2017000085A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Sunlidac在制备抗肺癌产品中的应用
US20200199681A1 (en) * 2016-11-14 2020-06-25 Virginia Commonweatlh University Mda-7 cancer therapies and methods of detecting biomolecules
CN108117594A (zh) * 2016-11-30 2018-06-05 财团法人工业技术研究院 促进细胞迁移及/或皮肤伤口愈合的肽、含该肽的医药组合物及其用途
CN111246876A (zh) * 2017-10-27 2020-06-05 弗吉尼亚联邦大学 包含mda-7/il-24蛋白的组合物和使用方法
CN109122581A (zh) * 2018-09-18 2019-01-04 南通市第二人民医院 Fra-1与XPA复合物在细胞周期调控中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) * 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5798339A (en) * 1990-12-17 1998-08-25 University Of Manitoba Treatment method for cancer
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1993009782A1 (en) * 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
DE4204650C1 (pt) * 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5643761A (en) * 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
JP2935950B2 (ja) * 1993-12-03 1999-08-16 株式会社山田製作所 ステアリングシャフト及びその製造装置
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6342379B1 (en) * 1995-06-07 2002-01-29 The Regents Of The University Of California Detection of transmembrane potentials by optical methods
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2248538A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6207145B1 (en) * 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US5739169A (en) * 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
WO1998004717A2 (en) * 1996-07-30 1998-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US5846225A (en) * 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US6207648B1 (en) * 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
US6180096B1 (en) * 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6350589B1 (en) * 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
US20030082140A1 (en) * 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
EP1534073A4 (en) * 2002-07-03 2005-09-14 Univ Columbia METHOD OF IDENTIFYING MODULATORS OF MDA-7-MEDIATED APOPTOSIS
AU2003274963A1 (en) * 2002-12-23 2004-07-29 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer

Also Published As

Publication number Publication date
KR20060002793A (ko) 2006-01-09
CA2518150C (en) 2015-08-11
JP2006523227A (ja) 2006-10-12
US20060134801A1 (en) 2006-06-22
EP1603943A2 (en) 2005-12-14
WO2004078124A3 (en) 2005-05-12
CN102836420B (zh) 2014-03-12
WO2004078124A2 (en) 2004-09-16
HK1180218A1 (en) 2013-10-18
CA2518150A1 (en) 2004-09-16
AU2004218407A2 (en) 2004-09-16
AU2004218407A1 (en) 2004-09-16
CN102836420A (zh) 2012-12-26
CN1759122A (zh) 2006-04-12
CN1759122B (zh) 2012-06-13

Similar Documents

Publication Publication Date Title
WO2004078124A3 (en) Methods and compositions involving mda-7
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
ATE408601T1 (de) Fredericamycin-derivate
UA84402C2 (ru) Применение монооксида углерода для лечения воспаления почек
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0316438C1 (pt) uso de eritropoietina em doenças cardíacas
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0411900A (pt) compostos antivirais e métodos
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BR0318498A (pt) composições terapêuticas à base de porìfero para o tratamento e a prevenção de doenças da pele
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BRPI0407234A (pt) Heterociclos substituìdos
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
BRPI0415249A (pt) terapia de combinação para infecção por hcv
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
PT1620113E (pt) Formulação tópica de ivermectina para o tratamento de condições dermatológicas
BRPI0408295A (pt) uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements